Mis Mahi Drugs Appoints New Cost Auditors and Nominee Director at Board Meeting
The Board of Directors of Mis Mahi Drugs Private limited, a material subsidiary of HALEOS LABS LIMITED, made significant appointments regarding its operational structure during a meeting held on August 5, 2026. The company appointed new cost auditors for the financial year 2026-27 and also named Mr. Vincent P. Asaro as a Nominee Director.The appointment of Annapragada & Co. as Cost Auditors was finalized at the meeting. This decision relates to Section 148 of the Companies Act, 2013, read with relevant rules governing audits and auditors.
Details regarding the Cost Auditor are presented below:
| Particulars | Information |
|---|---|
| Name of the Auditor and Firm Registration Number (FRN) | Annapragada & Co. (Formerly known as Harshitha Annapragada & Co.). IFRN: 0060311 |
| Reason for change (reappointment) | Appointed as Cost Auditors of the company. |
| Date of reappointment and term of appointment | Appointed for the financial year 2026-27. The appointment, which occurred in the Board Meeting held on 05.08.2026, will be subject to ratification by shareholders at the next Annual General Meeting. |
| Brief Profile | Accountants with good analytical and results driven experience in developing and implementing cost account systems and analyzing cost trends. The firm has exposure to Cost Audits, Finance, Forecasting, and process improvement. |
The company also appointed Mr. Vincent P. Asaro as a Nominee Director. This appointment is made following nomination by ChemWerth Inc., effective August 5, 2026, replacing Mr. M. Madhu Rao.
Detailed information regarding the appointed Nominee Director, Mr. Vincent P. Asaro, is provided in the table below:
| Particulars | Information |
|---|---|
| Name of the Director | Mr. Vincent P. Asaro |
| Director Identification Number (DIN) | 11827706 |
| Nationality | US Citizen |
| Education | He is a Certified Public Accountant (CPA) and holds an MBA In Finance from the University of Connecticut and a Bachelor of Science In Accounting from Providence college. He has also completed executive education at Harvard Business School. |
| Working Experience | Mr. Asaro is the President of ChemWerth Inc., a global developer and supplier of Active Pharmaceutical Ingredients (APIs) to regulated pharmaceutical markets worldwide. With over 35 years of experience in finance, corporate strategy, business development, and pharmaceutical operations, he has played a pivotal role in driving ChemWerth's growth. Prior to his appointment as President, he served as the Chief Financial Officer of ChemWerth Inc. since 2009. Earlier in his career, he held finance and leadership positions with Deloitte & Touche and Bayer. |
The information regarding these appointments is available on the company website, www.haleoslabs.com.
HALEOSLABS Stock Price Movement
Shares of HALEOS LABS LIMITED tumbled today, declining by 7.70% to settle at ₹1427.7 following the close. The stock faced considerable intraday pressure, hitting a low of ₹1400 and recording a traded volume of 2,482 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.